🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the battle against superbug strains of the bacteria, according to health experts.

An International Public Health Issue

Gonorrhoea infections are escalating around the world, with estimates suggesting more than 82 million instances annually. Especially elevated rates are observed in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary development in the reality of rising global incidence, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". Ongoing monitoring showed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Secure Approval

One new antibiotic, marketed under the name a brand name, was approved by the US FDA in December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts believe that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This approval marks a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

Based on findings detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the existing first-line therapy, which uses a dual-drug approach. The research involved hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the ability to license and sell the drug in many low-income and middle-income countries.

Clinicians directly involved have expressed optimism. Having a one-pill regimen of this kind is described as a "game-changer" for public health efforts. This is viewed as vital to alleviate the strain of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.